The DOI matches its Crossref record.
Single Daily Dose of Methimazole Compared to Every 8 Hours Propylthiouracil in the Treatment of Hyperthyroidism
Abstract
This study to compare single-dose and multiple-dose antithyroid therapy was prompted by a perceived lack of compliance in our University Medical Clinics by those patients using multidose regimens. Twenty-two hyperthyroid patients were randomly assigned to two therapy groups. Twelve received methimazole (Tapazole) 30 mg once daily in the morning; 10 received propylthiouracil 100 mg every 8 hours. Patients were seen every 4 weeks for 3 months and assessed clinically, as well as having the appropriate thyroid tests done. Univariate analysis revealed no difference in the two groups at baseline. Posttreatment assessment revealed the once-a-day methimazole therapy to be just as effective as propylthiouracil in improving thyroid indices and clinical markers. Compliance with methimazole was 83.3% compared to 53.3% with propylthiouracil. In conclusion, once-a-day methimazole was just as effective as propylthiouracil every 8 hours in this population. Compliance was also improved with the once-a-day therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dosage ratio of MMI to PTU of 1:20 is recommended when changing from one drug to another (115,319,480), although only two studies have examined this dosage ratio directly (115,319).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [319]
Citations
Cited by
Sorted by citations
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“For example, 15 mg of MMI would be roughly equivalent to 300 mg of PTU, but because the half-life of PTU is considerably shorter than that of MMI, the dose of PTU should be split over the day (481,482); for example, MMI 15 mg once daily may be substituted with PTU 100 mg three times a day (319).”
BackgroundAlexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042972 · Cited by 1,008
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K. G., & Pearce, S. H. S. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 1,025
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Cooper, D. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14073-1 · Cited by 384
Nakamura, H., Noh, J. Y., Itoh, K., Fukata, S., Miyauchi, A., Hamada, N., & Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves’ Disease (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2135 · Cited by 277
Antithyroid drug regimen for treating Graves’ hyperthyroidism
Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003420.pub4 · Cited by 249
An Optimal Treatment for Pediatric Graves’ Disease Is Radioiodine
Rivkees, S. A., & Dinauer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1239 · Cited by 158
Cooper, D. (2003) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2003-030185 · Cited by 142
Takata, K., Kubota, S., Fukata, S., Kudo, T., Nishihara, E., Ito, M., Amino, N., & Miyauchi, A. (2009) · Thyroid · doi:10.1089/thy.2008.0364 · Cited by 128
Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use
Rivkees, S. A., & Mattison, D. R. (2009) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/132041 · Cited by 135
“In comparison with PTU, MMI dosing is more convenient and associated with better compliance [67], as the tablets are small (5 or 10mg), and”
BackgroundEmiliano, A. B., Governale, L. A., Parks, M. A., & Cooper, D. S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2752 · Cited by 110
ANTITHYROID DRUGS FOR THE TREATMENT OF HYPERTHYROIDISM CAUSED BY GRAVES' DISEASE
Cooper, D. S. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70308-x · Cited by 101
Diagnosis and Treatment of Graves Disease
Streetman, D. D., & Khanderia, U. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c299 · Cited by 101
Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use
Rivkees, S., & Mattison, D. (2009) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2009-132041 · Cited by 90
Controversies in the management of Graves’ disease in children
Rivkees, S. A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0477-x · Cited by 77
Léger, J., Petit, I., Rodrigue, D., Lambert, A.-S., & Coutant, R. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.08.001 · Cited by 70
Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action
Mondal, S., & Mugesh, G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.04.006 · Cited by 58
Current and emerging treatment options for Graves’ hyperthyroidism
Abraham, P., & Acharya (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5229 · Cited by 57
Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016
Minamitani, K., Sato, H., Ohye, H., Harada, S., & Arisaka, O. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.29 · Cited by 54
Nayak, B. M., & Hodak, S. P. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.06.002 · Cited by 54
The safety and efficacy of antithyroid drugs
Azizi, F. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.107 · Cited by 52
“Therefore, whereas methimazole may be administered once or twice daily, propylthiouracil needs to be used 2 – 3 times daily [27,29,30].”
BackgroundTrepanier, L. A., Hoffman, S. B., Kroll, M. M., et al. (2003) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2003.222.954 · Cited by 48
Pediatric Graves’ disease: management in the post-propylthiouracil Era
Rivkees, S. A. (2014) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2014-10 · Cited by 46
“Although MMI is often prescribed in divided doses over the day, once a day dosing is sufficient [14] and is associated with better compliance than multiple daily doses [15].”
BackgroundHe, C.-T., Hsieh, A.-T., Pei, D., Hung, Y.-J., Wu, L.-Y., Yang, T., Lian, W., Huang, W.-S., & Kuo, S.-W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02032.x · Cited by 47
Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism
Homsanit, M., Sriussadaporn, S., Vannasaeng, S., Peerapatdit, T., Nitiyanant, W., & Vichayanrat, A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01239.x · Cited by 48
ENDOCRINOLOGY IN PREGNANCY: Pregnancy and the incidence, diagnosing and therapy of Graves’ disease
Laurberg, P., & Andersen, S. L. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0410 · Cited by 42
Sato, H., Minagawa, M., Sasaki, N., Sugihara, S., Kazukawa, I., Minamitani, K., Wataki, K., Konda, S., Inomata, H., Sanayama, K., et al. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.194 · Cited by 33
Hyperthyroidism: advantages and disadvantages of medical therapy
Pearce, E. N., & Braverman, L. E. (2004) · Surgical Clinics of North America · doi:10.1016/j.suc.2004.01.007 · Cited by 28
“The once-daily dose of MMI has been shown to improve patient compliance [20].”
BackgroundPharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism
Abbara, A., Clarke, S. A., Brewster, R., Simonnard, A., Eng, P. C., Phylactou, M., Papadopoulou, D., Izzi‐Engbeaya, C. N., Sam, A. H., Wernig, F., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00286 · Cited by 27
“Moreover, compliance is increased by once daily dosing of ATD (43).”
BackgroundFortnightly review: Controversial aspects of thyroid disease
Hanna, F., Lazarus, J. H., & Scanlon, M. F. (1999) · BMJ · doi:10.1136/bmj.319.7214.894 · Cited by 24
Sato, H., Harada, S., Yokoya, S., Tanaka, T., Asayama, K., Mori, M., & Sasaki, N. (2007) · Thyroid · doi:10.1089/thy.2006.0193 · Cited by 18
Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
García-Mayor, R. V., & Larrañaga, A. (2010) · Medicinal Chemistry · doi:10.2174/1573406411006040239 · Cited by 18
Sriussadaporn, S., Pumchumpol, W., Lertwattanarak, R., & Kunavisarut, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/2619695 · Cited by 12
Should radioiodine be the first-line treatment for paediatric Graves’ disease?
West, J. D., Cheetham, T. D., Dane, C., & Natarajan, A. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0176 · Cited by 9
Tratamento do hipertireoidismo da Doença de Graves
Andrade, V. A., Gross, J. L., & Maia, A. L. (2001) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302001000600014 · Cited by 9
Fadeev, V. V. (2020) · Clinical and experimental thyroidology · doi:10.14341/ket12474 · Cited by 9
Thionamide-induced Agranulocytosis: A Retrospective Analysis of 36 Patients With Hyperthyroidism
Zhu, D., Zhang, S., Cao, X., Xia, Q., Zhang, Q., Deng, D., Gao, S., Yu, H., Liu, Y., Zhou, H.-Y., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.017 · Cited by 6
Treatment outcome of Graves' disease in Thai children.
Somnuke, P. H., Pusuwan, P., Likitmaskul, S., Santiprabhob, J., & Sawathiparnich, P. (2007) · PubMed · Cited by 6
Iwaki, H., Ohba, K., Okada, E., Murakoshi, T., Kashiwabara, Y., Hayashi, C., Matsushita, A., Sasaki, S., Suda, T., Oki, Y., et al. (2020) · European Thyroid Journal · doi:10.1159/000509324 · Cited by 6
Pradhan, S., Sarma, H., Bharadwaz, B., & Mattaparthi, V. S. K. (2017) · Journal of Molecular Imaging & Dynamics · doi:10.4172/2155-9937.1000131 · Cited by 5
Antithyroid Drugs for the Treatment of Graves Disease
Peixoto, M. C., Buescu, A., alves, M. R. B. G., Albernaz, M. D. S., Coeli, C. M., & Vaisman, M. (2006) · The Endocrinologist · doi:10.1097/01.ten.0000249137.35809.b3 · Cited by 4
Hyperthyroidism - Recent Updates
Gelen, V., Kükürt, A., & Şengül, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100994 · Cited by 3
Buldygina, Y. V., Strafun, L. S., Terekhova, H. М., Shlyakhtych, S. L., & Pankiv, V. І. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.2.2019.166111 · Cited by 3
Watanabe, N., Noh, J. Y., Akamizu, T., & Yamada, M. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0238 · Cited by 12
Therapeutic Options in Graves’ Hyperthyroidism
Bhat, J. A., Patto, S. M., Sharma, P., Bhat, M. H., & Mir, S. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106562 · Cited by 3
Selim, S., Pathan, M. F., Rahman, M., Saifuddin, M., Qureshi, N. K., Mir, A. S., Afsana, F., Haq, T., Kamrul-Hasan, A. B. M., & Ashrafuzzaman, S. (2023) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_2_23 · Cited by 3
Graves' disease in Albanian children.
Gjikopulli, A., Tomori, S., Kollçaku, L., et al. (2015) · PubMed · doi:10.12865/chsj.40.03.06 · Cited by 3
Methimazole-induced urticaria in hyperthyroid patients: A safe re-administration protocol
Chahed, F., Fredj, N. B., Romdhane, H. B., Chadli, Z., Chaabane, A., Fadhel, N. B., & Aouam, K. (2024) · Therapies · doi:10.1016/j.therap.2023.12.006 · Cited by 2
McDermott, M., & Ridgway, E. C. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-5 · Cited by 2
Hollander, J. M., & Davies, T. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4745-2.00012-2 · Cited by 1
Hyperthyroidism Due to Graves’ Disease, Toxic Nodules and Toxic Multinodular Goiter
Burman, K. D. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-3 · Cited by 1
Treatment of Grave’s Disease in Adults
Álvarez, M., & Duarte, L. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97563 · Cited by 1
Bhatt, S. J., Pinho, G., & Morelli, S. S. (2019) · Topics in Obstetrics & Gynecology · doi:10.1097/01.pgo.0000615660.61696.20 · Cited by 1
Rivkees, S. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_11
Diabetes in the new General Medical Services contract: targets and adherence to metformin therapy
Kirby, M. G. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00511b.x
Kaplan, M. M., & Meier, D. A. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_10
Rogers, J. P. M. P. A. M. (2011) · CRC Press eBooks · doi:10.1201/b13389-25
Predictors of TSH Normalization in Thyrotoxicosis Patients after TreatmentPreprint
Han, C. H., Yin, C.-H., Chen, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3998417/v1
Cooper, D. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-277-7_4
Selim, S., Tanni, A. Z., Afsana, F., Rahman, M. A., Mohiuddin, S. M., Mahjabeen, S., Rahman, M. H., Rahman, S. I., Saifuddin, M., Ferdous, C., et al. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_45_25
Metadata
- Authors
- NICHOLAS, W. C., FISCHER, R. G., STEVENSON, R. A., & BASS, J. D.
- Affiliations
- University of Mississippi Medical Center (US)
- Venue
- Southern Medical Journal
- Publisher
- Southern Medical Association
- Published
- 1995-09
- Volume
- 88
- Issue
- 9
- Pages
- 973-976
- ISSN
- 0038-4348 (ISSN-L)
- OpenAlex
- W1535496843
- Cited by
- 64
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 2 · 2014: 2
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Southern Medical Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Keywords
- hyperthyroidism, methimazole, propylthiouracil, once-daily dosing, medication adherence, treatment efficacy, thyroid function tests
- MeSH terms
- Drug Administration Schedule, Female, Humans, Hyperthyroidism, Male, Methimazole, Patient Compliance, Propylthiouracil, Thyrotropin, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
